Cytokinetics is committed to supporting patients with MYQORZO & You™, a personalized program for patients prescribed MYQORZO ...

Long-term oral β-blocker therapy, including bisoprolol, metoprolol, and carvedilol, reduces the composite endpoint of all-cause death, new myocardial infarction, or heart failure by 25% in ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incor ...

Study links exosomal microRNA to ventricular remodelling in heart failure. Discover how this biomarker could inform future ...

CVRx’s stock has risen nearly 20% after the company revealed that its heart failure device is set to be investigated in an ...

ELPIS II top-line trial results are anticipated in the third quarter of 2026Laromestrocel Biological License Application (BLA) submission for ...

Heart failure is a chronic condition in which the heart cannot pump blood and oxygen effectively enough to support other organs.

Investing.com -- CVRx Inc. (NASDAQ:CVRX) stock rose 2.9% in after-hours trading Thursday following the company’s announcement of a landmark clinical trial that could significantly expand the patient ...

Here's where I'd be investing my money. The post 3 Australian stocks tipped to grow 100% (or more) in 2026 appeared first on ...

Study is Expected to Be One of the Largest Therapeutic Cardiac Device Trials in Heart Failure Ever Performed, and is ...

To determine the best path forward, you need to work with a cardiologist. They will review the tests you had and can ...

with the Disease, Inspired by the Experience with HCM of ...